Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment von Flanagan, S, Minassian, S L, Morris, D, Ponnuraj, R, Marbury, T C, Alcorn, H W, Fang, E, Prokocimer, P

Volltext

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus von Lawitz, E., Freilich, B., Link, J., German, P., Mo, H., Han, L., Brainard, D. M., McNally, J., Marbury, T., Rodriguez-Torres, M.

Volltext

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study von Rodriguez-Torres, M., Glass, S., Hill, J., Freilich, B., Hassman, D., Di Bisceglie, A. M., Taylor, J. G., Kirby, B. J., Dvory-Sobol, H., Yang, J. C., An, D., Stamm, L. M., Brainard, D. M., Kim, S., Krefetz, D., Smith, W., Marbury, T., Lawitz, E.

Volltext

An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment von Peterson, L., Marbury, T., Marier, J., Laliberte, K.

Volltext

THU0138 Pharmacokinetics of fostamatinib in patients with impaired renal function: A phase I study von Martin, P., Oliver, S., Gillen, M., Marbury, T., Millson, D.

Volltext

THU0139 Pharmacokinetics of fostamatinib in patients with impaired hepatic function: A phase I study von Martin, P., Oliver, S., Gillen, M., Marbury, T., Millson, D.

Volltext

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment von Mogalian, E, Mathias, A, Brainard, D, Shen, G, McNally, J, Sajwani, K, Robson, R, Ries, D, Lasseter, K, Marbury, T

Volltext

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease von Courtney, R., Sansone, A., Smith, W., Marbury, T., Statkevich, P., Martinho, M., Laughlin, M., Swan, S.

Volltext

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension von CHARYSANT, S. G, MARBURY, T. C, ROBINSON, T. D

Volltext

The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, a Pan-Genotypic HCV NS3/4A Protease Inhibitor von Lawitz, E, Marbury, T, Kirby, B.J, Au, N.T, Mathias, A, Stamm, L.M, Wei, H, Sajwani, K, Klein, G, Gane, Ed, Robson, R

Volltext

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C von Brennan, B. J., Morcos, P. N., Wang, K., Blotner, S. D., Morrison, R., Hagedorn, C. H., Marbury, T. C., Sulkowski, M., Grippo, J. F.

Volltext

Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension von Oparil, Suzanne, Williams, David, Chrysant, Steven G., Marbury, Thomas C., Neutel, Joel

Volltext

P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study von Rodriguez-Torres, M, Glass, S, Hill, J, Freilich, B, Hassman, D, Di Bisceglie, A, Taylor, J.G, Kirby, B, Yang, J.C, Stamm, L.M, Brainard, D.M, Kim, S, Krefetz, D, Smith, W, Marbury, T, Lawitz, E

Volltext

Pharmacokinetics of repaglinide in subjects with renal impairment von Marbury, Thomas C., Ruckle, Jon L., Hatorp, Vibeke, Andersen, Michael P., Nielsen, Karin Kramer, Huang, Won Chin, Strange, Poul

Volltext

1211 NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HCV GT-1 PATIENTS von Vince, B, Lawitz, E, Searle, S, Marbury, T, Robison, H, Robarge, L, Olek, E

Volltext

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT von Mogalian, E, Mathias, A, Brainard, D, McNally, J, Moorehead, L, Hernandez, M, Perry, R, Curtis, C, Lawitz, E, Lasseter, K, Marbury, T

Volltext

593 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI) von Venkatakrishnan, K, Liu, Y, Noe, D, Mertz, J, Mockler, M, Marbury, T, Farbakhsh, K, Oliva, C, Milton, A

Volltext

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval von Iwamoto, M., Kost, J. T., Misty, G. C., Wenning, L. A., Breidinger, S. A., Marbury, T. C., Stone, J. A., Gottesdiener, K. M., Bloomfield, D. M., Wagner, J. A.

Volltext

1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C von Lawitz, E, Gruener, D, Marbury, T, Hill, J, Webster, L, Hassman, D, Pflanz, S, Massetto, B, Subramanian, M, McHutchison, J, Jacobson, I.M, Freilich, B, Rodriguez-Torres, M

Volltext

847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS von Lawitz, E, Hill, J, Vince, B, Murillo, A, Gruener, D, Marbury, T, Demicco, M, Agarwal, A, Robison, H, Huang, M, Robarge, L, Hui, J, Olek, E, Deshpande, M, Kocinsky, H

Volltext